In vitro drug sensitivity testing using an established SCCC organoid revealed that among the two therapeutic targets of precision medicine identified, the KRAS pathway inhibitor exerted adequate anti‐cancer effects compared to the MYC inhibitor. Here, KRAS is linked to cancer.